Despite their well-known anti-inflammatory effects, glucocorticoids (GCs) could contribute to breast cancer initiation, progression, and survival via the activation of the glucocorticoid receptor (GR) or by increasing aromatase expression via the GC response element (GRE) on exon I.4 of the CYP19A1 gene (26). Here, NR3C1 is linked to breast carcinoma.